Sinovac Biotech, Ltd (SVA) Misses Q3 EPS by 3c

Sinovac Biotech, Ltd (NASDAQ: SVA) reported Q3 EPS of ($0.06), $0.03 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $14.3 million versus the consensus estimate of $12.35 million.

For earnings history and earnings-related data on Sinovac Biotech, Ltd (SVA) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• Lumexa Imaging Holdings, Inc. (LMRI) Reports In-Line Q2 EPS; Offers Guidance
• Acrivon Therapeutics, Inc. (ACRV) Tops Q2 EPS by 21c